Get started
Author

Yoshihiko Sakata

Observed name: Y. Sakata
ORCID: 0000-0002-3300-9138
Observed ORCID: 0000-0002-3300-9138
OpenAlex ID: A5024164352
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
2021 · Yoshihiko Sakata, Shinya Sakata, et al. · European Journal of Cancer · 101
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)
2021 · Go Saito, Yuko Oya, et al. · Lung Cancer · 63
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer
2022 · Yuki Sato, Hiromitsu Sumikawa, et al. · CHEST Journal · 52
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment
2019 · Yoshihiko Sakata, Kodai Kawamura, et al. · Lung Cancer · 46
Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis
2016 · Kodai Kawamura, Kazuya Ichikado, et al. · SpringerPlus · 40
PDF
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
2023 · Daichi Fujimoto, Takeshi Morimoto, et al. · JAMA Network Open · 32
PDF
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors
2019 · Yoshihiko Sakata, Kodai Kawamura, et al. · Thoracic Cancer · 30
PDF
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
2022 · Mihoko Imaji, Daichi Fujimoto, et al. · European Journal of Cancer · 24
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
2022 · Hayato Kawachi, Motohiro Tamiya, et al. · JTO Clinical and Research Reports · 18
Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer
2016 · Yoshihiko Sakata, Kodai Kawamura, et al. · Lung Cancer · 18
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
2023 · Yoshihiko Sakata, Go Saito, et al. · Lung Cancer · 16
The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events
2018 · Yoshihiko Sakata, Kodai Kawamura, et al. · Asia-Pacific Journal of Clinical Oncology · 14
PDF
Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease
2017 · Tatsuya Nitawaki, Yoshihiko Sakata, et al. · BMC Pulmonary Medicine · 14
PDF
Hermansky–Pudlak syndrome type 4 with interstitial pneumonia
2013 · Yoshihiko Sakata, Kodai Kawamura, et al. · Respiratory Medicine Case Reports · 13
PDF
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
2024 · Yuki Katayama, Tadaaki Yamada, et al. · Clinical Cancer Research · 11
Real-world survey of pneumonitis/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval: A multicenter retrospective cohort study (HOPE-005/CRIMSON).
2020 · Go Saito, Yuko Oya, et al. · Journal of Clinical Oncology · 10
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
2022 · Hideki Terai, Kenzo Soejima, et al. · JTO Clinical and Research Reports · 9
PDF
Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy
2025 · Kentaro Hirade, Noritaka Tanaka, et al. · Cell Reports Medicine · 7
PDF
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
2025 · Yoshihiko Sakata, Go Saito, et al. · Clinical Lung Cancer · 7
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
2024 · Ryota Shibaki, Daichi Fujimoto, et al. · Lung Cancer · 7
Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia
2021 · Kazuya Ichikado, Kodai Kawamura, et al. · Scientific Reports · 6
PDF
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study
2025 · Asuka Okada, Yoshihiko Sakata, et al. · Lung Cancer · 5
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
2024 · Jun Sugisaka, Daichi Fujimoto, et al. · Lung Cancer · 5
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
2024 · Hayato Kawachi, Motohiro Tamiya, et al. · Clinical Lung Cancer · 5
PDF
Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study
2024 · Yosuke Kakiuchi, Koichi Saruwatari, et al. · Clinical Lung Cancer · 5
PDF
Works count: 52
Citation count: 581
H-index: 13
I10-index: 16
Year
Topic
Type